Catenion Management Consulting for Pharmaceutical and Medical Products Companies

Catenion is a management consulting firm devoted to helping pharmaceutical and medical products companies significantly increase the returns on their research and development (R&D) and marketing investments by creating more innovative and effective strategies and organisations.

We greatly improve how our clients assess the value and risk of their project and product portfolios and how they allocate resources. We also address the cultural impediments to pharmaceutical innovation by helping clients create the organisational climates that foster creativity and medical breakthroughs. Furthermore, we draw on our deep understanding of industry trends and company dynamics to help our clients develop actionable competitive strategies.

We work with board directors, CEOs, business unit general managers, heads of R&D, finance, strategy, portfolio management and business development and other executives who want to improve the performance of their organisation.

Strategy development and innovation management for pharmaceutical and medical products companies

Catenion specialises in strategy development and innovation management for pharmaceutical and medical products companies. It is our sole focus. We possess and continually develop leading approaches to key aspects of R&D strategy, such as asset valuation, risk assessment and portfolio management.

We bring highly experienced consultants with in-depth expertise in the economic, marketing, scientific and organisational effectiveness issues of life sciences R&D who deliver a cross–disciplinary approach to their work. Our consultants are passionate about transferring their knowledge and capabilities to clients.

We develop a strong, independent point of view rooted in the objective reality and requirements of our clients as we see them.

Decision analysis services for the pharmaceutical and medical products industries

Our uniqueness begins with a deep understanding of what really counts in the pharmaceutical and medical products industries.

We are convinced that the core element of success in this industry is not to develop fancy ‘winning strategies’. Rather, we believe the key is to build organisations that can make good decisions in the face of unusually high risks and long timelines.

This is why we have focused on understanding what drives the behaviour and creativity of scientists, technicians and managers, as well as developing tools and methods for decision analysis that address the specific requirements of this industry.

We do not claim to bring ready-made answers to our clients, but we have developed an in-depth understanding of the key drivers of the industry, and our partners and consultants are well-equipped to challenge scientists and executives so as to improve the quality of decision-making in R&D projects, therapeutic areas and the company overall.

Management consulting services for pharmaceutical and medical companies

A number of principles have shaped, and will continue to shape, our firm:

  • Creativity, drive and intrinsic motivation
  • Full empathy with clients and their problems
  • Intellectual honesty and an open mind
  • An understanding of the big picture and attention to detail
  • Modesty and self-awareness

As a result, we continually perfect and re-invent our approaches and analytical methods, always go the extra mile, and are much better at delivering our services than at selling ourselves.

Educational programmes for improved risk mitigation in pharmaceutical R&D and BD&L

The Catenion Academy is the educational arm of Catenion. We help pharmaceutical professionals to reduce the risks involved in bringing new drugs to market and improve complex decision-making. Our goal is to sharpen strategic thinking and improve risk mitigation in pharmaceutical R&D and BD&L.

The Catenion Academy provides three types of educational programmes: Risky Business, the pharmaceutical industry board game; in-depth courses on decision analysis techniques; and customised programmes. Our programmes are based on proprietary consulting approaches developed by Catenion – approaches that have helped to address and solve strategic issues for many of the world’s leading pharmaceutical companies.

Make an enquiry

Follow this company

Follow the company to be always up to date with this company

Press Release

Exclusive Cooperation Between ARTES and IPK

ARTES Biotechnology GmbH expands technology platform Having achieved notable success with the Hansenula technology for years, the biotech company ARTES has now concluded an exclusive partnership with the internationally renowned Leibniz Institute of Plant Genetics and Crop Plant

Address
Catenion GmbH

Hausvogteiplatz 12

10117 Berlin

Other

Germany

+49 30 2063 9960 +49 30 2063 99022 www.catenion.com Client Testimonials

Catenion Images

Products and Services

Video

White Papers

Press Release

8 March 2011

Fujifilm Corporation and Merck, known as MSD outside the US and Canada, have announced that they have entered into a definitive agreement by which Fujifilm will acquire the Merck BioManufacturing Network, a leading provider of contract manufacturing and development services for the biopharmaceut

Read more
8 October 2007

ARTES Biotechnology GmbH expands technology platform Having achieved notable success with the Hansenula technology for years, the biotech company ARTES has now concluded an exclusive partnership with the internationally renowned Leibniz Institute of Plant Genetics and Crop Plant

Read more
17 July 2007

"We are looking forward to working with an international team“, says Dr Melanie Dröttboom, head of business development of Artes Biotechnology GmbH. Biotech company Artes, based near Düsseldorf, has been confirmed that it is developing an aptamer-based microarray for

Read more
29 May 2007

ACE Pharmaceuticals today announced that the first patient has entered the Phase III trial also known as the Levamisole trial. This trial was accepted by the EMEA by November 2006. The goal of this trial, which was accepted by the EMEA in November 2006, is to assess the efficacy and sa

Read more
9 January 2007

ARTES announces the grant of the European patent on increasing recombinant protein secretion in yeast by co-expression of Calnexin, a protein responsible in intracellular quality control and sorting. In extensive studies, ARTES could show that overexpression of Calnexin results in sign

Read more
19 June 2006

Kiel - Erkrath, June 19, 2006. PROTEO Biotech AG, a wholly owned subsidiary of PROTEO Inc., USA, has signed a cooperation agreement with ARTES Biotechnology GmbH. The aim of the agreement is the marketing of Elafin, the lead product of PROTEO Biotech AG / PROTEO Inc., in India, Egypt and Argentin

Read more

Regional Offices

Catenion GmbH

Hausvogteiplatz 12

10117 Berlin

Other

Germany

+49 30 2063 9960 +49 30 2063 99022 www.catenion.com Client Testimonials

Contact company

I have read and accept the terms and conditions and privacy policy.
We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.
If you would like to hear from carefully selected third party companies, check this box
Follow this company to receive notifications when they update.